Skip to main content

Foresite Capital — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

129
Companies
$15.2B
Total invested
$143.0M
Avg. check
22
Industries
Biotechnology 20Health Care 19Life Science 9Therapeutics 8Pharmaceutical 5Medical 4+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 129
Alector
November 2024

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Biotechnology · San Francisco$50.0M Post Ipo Debt
Relay Therapeutics
September 2024

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.

Biotechnology · Cambridge$200.0M Post Ipo Equity
Foresight Diagnostics
July 2024

Foresight Diagnostics develops novel technology for detect cancers from a simple blood draw.

Biotechnology · Denver$33.0M Series B
Spear Bio
July 2024

Spear Bio is a biotech company that focuses on the detection of ultrasensitive protein.

Biotechnology · Weston$45.0M Series A
Cerevance
April 2024

Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases.

Biotechnology · Boston$47.0M Series B
Xaira Therapeutics
April 2024

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.

Artificial Intelligence (AI) · South San Francisco$1.0B Series A
Cullinan Therapeutics
April 2024

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Biopharma · Cambridge$280.0M Post Ipo Equity
Obsidian Therapeutics
April 2024

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Biotechnology · Cambridge$160.5M Series C
ImmPACT Bio
February 2024

ImmPACT Bio USA is developing novel cell therapies for treating cancer.

Biotechnology · Camarillo$8.0M Grant
Remix Therapeutics
January 2024

Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.

Biotechnology · Cambridge$60.0M Series Unknown
Keros Therapeutics
January 2024

Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.

Biotechnology · Lexington$140.0M Post Ipo Equity
Generation Bio
March 2023

Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.

Biotechnology · Cambridge$76.0M Post Ipo Equity
Inscripta
January 2023

Inscripta is a life science technology company that develops digital genome engineering solutions.

Biotechnology · Pleasanton$4.4M Series Unknown
Mindstrong Health
September 2022

Mindstrong is a virtual mental health platform.

Health Care · Menlo Park$250K Grant
Twist Bioscience
February 2022

Twist Bioscience is a biotechnology company that offers synthetic DNA solutions, gene synthesis, and variant libraries.

B2B · San Francisco$250.0M Post Ipo Equity
Cue
January 2022

Cue is a healthcare technology company that enables people to manage their health through actionable and connected health data.

Health Care · San DiegoGrant
Velia
January 2022

Velia is a biotech company that discovers and develops the therapeutic potential of human proteins.

Biotechnology · San Diego$55.0M Series A
Pardes Biosciences
December 2021

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.

Biotechnology · Carlsbad$75.0M Post Ipo Equity
Tasso
December 2021

Tasso is a Medical innovation company changing the way diagnostics are delivered

Health Care · Seattle$100.0M Series B
Mythic Therapeutics
December 2021

Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics.

Biotechnology · Waltham$103.0M Series B
XinThera
August 2021

XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.

Biotechnology · San Diego$50.0M Series B
Tesseract Health
April 2021

Tesseract Health provides devices for disease monitoring and prevention.

Health Care · Guilford$80.0M Series B
Theseus Pharmaceuticals
April 2021

Theseus Pharmaceuticals is a technology-based company.

Biotechnology · New York$100.0M Series B
Gemini Therapeutics
February 2021

Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.

Biopharma · Cambridge$95.0M Post Ipo Equity

Where Foresite Capital invests

Biotechnology20
Health Care19
Life Science9
Therapeutics8
Pharmaceutical5
Medical4

About Foresite Capital's portfolio

How many companies has Foresite Capital invested in?

Foresite Capital has invested in 129 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Foresite Capital invest in?

Foresite Capital's top investment sectors include Biotechnology, Health Care, Life Science, Therapeutics, Pharmaceutical. The firm invests across 22 different industry categories.

What is Foresite Capital's largest investment?

Among tracked funding rounds, Xaira Therapeutics received $1.0B in a Series A round. Foresite Capital's total known invested capital is $15.2B.

What is the average investment size for Foresite Capital?

Foresite Capital's average investment size is $143.0M across its portfolio of 129 companies.

What are Foresite Capital's most recent investments?

Recent Foresite Capital portfolio additions include Alector, Relay Therapeutics, Foresight Diagnostics, Spear Bio, Cerevance. These companies were founded in 2020 or later.

Reach the founders behind these 129 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →